Status:
RECRUITING
Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement
Lead Sponsor:
University of Minnesota
Conditions:
Total Shoulder Arthroplasty
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The use of ISB in patients undergoing total shoulder arthroplasty (TSA) is the gold standard and results in significantly reduced pain scores and opioid use. However, patients still have pain and the ...
Eligibility Criteria
Inclusion
- Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty;
- Patients aged 18-85 years old.
Exclusion
- Patients who have an exclusion to regional anesthesia such as pre-existing nerve damage to their brachial plexus or infection at the site of injection.
- Patients who have exclusion to interscalene blockade such as severe lung disease.
- Non-English speakers will be excluded because pain scales are not validated in other languages and there is lack of standardization of pain reporting.
- Pregnant patients
- Patients who are currently using opioids and patients with a diagnosis of chronic pain will be excluded.
Key Trial Info
Start Date :
March 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06143306
Start Date
March 20 2024
End Date
May 1 2027
Last Update
February 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455